CP1-administered prostate tumors contained an increased percentage of HMGB1− nuclei (Fig. 2c), signifying HMGB1 release24, and areas of increased cell surface calreticulin levels (Fig. 2d). The gene discussed is CALR; the disease is prostate neoplasm.